Literature DB >> 9138718

Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test.

G Rozas1, J L Labandeira García.   

Abstract

A variety of tests are available for the evaluation of behavioural deficits in rat models of hemiparkinsonism; many, however, are of limited applicability or insufficiently objective. The drug-induced turning behaviour test is widely used. A disadvantage of this test is that the use of drugs may lead to misleading results. Here, we describe a drug-free rotarod test that was used to evaluate the effects of unilateral 6-hydroxydopamine lesions, nigral grafts, and subrotational doses of apomorphine. The rotarod unit was automated and interfaced to a personal computer allowing automatic recording of the time that each rat was able to stay on the rod at different rotational speeds (i.e., progressively increasing the difficulty of the task). A combination of lesion-induced deficits resembling those of Parkinson's disease appears to be involved in falling from the rod. The test shows high effectiveness for identifying rats with maximal dopaminergic lesions, but is also effective for identifying partial lesions. Rotarod performance profiles were useful for investigating the effects of intrastriatal nigral grafts, since low rotation speeds revealed differences from lesioned rats (i.e., improvements) while higher speeds revealed differences from normal rats (i.e., remaining deficits and partial lesions). The test was effective regardless of whether rats were trained on the rod before lesion, after lesion, or after grafting. Injections of apomorphine (0.0125 and 0.0250 mg/kg) did not induce consistent improvements. These results indicate that the rotarod test is a useful drug-free procedure for overall evaluation of basic motor abilities in rat models of parkinsonism and treatment-induced changes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138718     DOI: 10.1016/S0006-8993(96)01162-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  25 in total

1.  Quantitative assessment of neurologic deficits in a chronic progressive murine model of CNS demyelination.

Authors:  D B McGavern; L Zoecklein; K M Drescher; M Rodriguez
Journal:  Exp Neurol       Date:  1999-07       Impact factor: 5.330

2.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

3.  Suppression of endogenous PPARγ increases vulnerability to methamphetamine-induced injury in mouse nigrostriatal dopaminergic pathway.

Authors:  Seong-Jin Yu; Mikko Airavaara; Hui Shen; Jenny Chou; Brandon K Harvey; Yun Wang
Journal:  Psychopharmacology (Berl)       Date:  2011-12-13       Impact factor: 4.530

4.  Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.

Authors:  Lori M Gorton; Marta G Vuckovic; Nina Vertelkina; Giselle M Petzinger; Michael W Jakowec; Ruth I Wood
Journal:  Behav Brain Res       Date:  2010-05-21       Impact factor: 3.332

Review 5.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

6.  Decreased entropy modulation of EEG response to novelty and relevance in schizophrenia during a P300 task.

Authors:  Alejandro Bachiller; Alba Lubeiro; Álvaro Díez; Vanessa Suazo; Cristina Domínguez; José A Blanco; Marta Ayuso; Roberto Hornero; Jesús Poza; Vicente Molina
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-28       Impact factor: 5.270

7.  Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Authors:  Ludovico Arcuri; Salvatore Novello; Martina Frassineti; Daniela Mercatelli; Clarissa Anna Pisanò; Ilaria Morella; Stefania Fasano; Blair V Journigan; Michael E Meyer; Willma E Polgar; Riccardo Brambilla; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2018-01-31       Impact factor: 8.739

Review 8.  Neurobehavioural Changes in a Hemiparkinsonian Rat Model Induced by Rotenone.

Authors:  Sukala Puthuparambil Maniyath; Narayanan Solaiappan; Muthusamy Rathinasamy
Journal:  J Clin Diagn Res       Date:  2017-03-01

9.  Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Authors:  Ludovico Arcuri; Riccardo Viaro; Simone Bido; Francesco Longo; Mariangela Calcagno; Pierre-Olivier Fernagut; Nurulain T Zaveri; Girolamo Calò; Erwan Bezard; Michele Morari
Journal:  Neurobiol Dis       Date:  2016-01-22       Impact factor: 5.996

10.  Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease.

Authors:  Dianne M Camp; David A Loeffler; Diane M Farrah; Jade N Borneman; Peter A LeWitt
Journal:  J Neuroinflammation       Date:  2009-06-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.